Kangzhi Pharmaceutical Co., Ltd. and Guangdong Institute of Public Health signed the “Research Cooperation Agreement on Horizontal Scientific Research Projects”

2022-05-04 0 By

Recently, Guangdong Kangda Pharmaceutical Co., LTD., a wholly-owned subsidiary of Kangzhi Pharmaceutical Co., LTD., and Guangdong Institute of Public Health officially signed the “Horizontal Research Project research cooperation Agreement”.Since the outbreak of COVID-19 in 2020, Kangzhi Pharmaceutical, as a listed pharmaceutical enterprise in China, has been actively carrying out anti-epidemic research.The signing of this “Cooperation Agreement on Horizontal Research Projects” is to carry out further horizontal research and development of Sodium Suramin for injection on the basis of the previous fund support of “Guangdong Provincial Novel Coronavirus Science and Technology Special Project” of Guangdong Provincial Science and Technology Department.Kangzhi Pharmaceutical has obtained the clinical approval for suramin sodium for injection for the treatment of hand, foot and mouth disease in 2018.At present, Kangzhi Pharmaceutical has completed phase I clinical trial of suramin sodium for injection for hand, foot and mouth disease, and obtained the approval of phase II clinical trial for indication of “acute kidney injury”. It is a product under development and has not been marketed yet.(Disclaimer: the content of this article is published or reproduced by this website, which only represents the author’s personal views and has nothing to do with this website.For readers’ reference only, and please verify the relevant content.)